Jubilant Pharmova Q2 Results FY27: Profit Moves Against Revenue, Revenue Rs 2,370 Cr, PAT Rs 31 Cr
- November 14, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Jubilant Pharmova Q2 Results FY27 were declared on 13 November 2026, with consolidated revenue of Rs 2,370 Cr, a YoY growth of 20.52% over Rs 1,966.4 Cr a year earlier. Net profit stood at Rs 31 Cr against Rs 119.9 Cr, a decline of 74.15%, so the quarterly results show revenue and profit moving in opposite directions. Operating Profit was Rs 240.5 Cr, down 29.55% on the Consolidated basis.
Jubilant Pharmova Ltd (JUBLPHARMA) Q2 Results FY27 announced on 13 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated results showing revenue of Rs 2,370 Cr, up YoY, and PAT of Rs 31 Cr, down YoY. Univest presents these Jubilant Pharmova Q2 Results FY27 figures on the Consolidated basis.
This Jubilant Pharmova Q2 Results review adds a results analysis covering the financial highlights, business drivers, outlook and risks. It starts with the Financial Highlights table, which places revenue, Operating Profit and net profit for the quarter beside the same quarter last year.
Click Here – Get Free Investment Predictions
Jubilant Pharmova Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 2370 Cr | Rs 1966.4 Cr | +20.52% YoY |
| Operating Profit | Rs 240.5 Cr | Rs 341.4 Cr | -29.55% YoY |
| Net Profit (PAT) | Rs 31 Cr | Rs 119.9 Cr | -74.15% YoY |
Source: company filing for Jubilant Pharmova Q2 Results FY27, 13 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Jubilant Pharmova Q2 Results: What Stands Out
- Revenue of Rs 2,370 Cr: sales rose 20.52% from Rs 1,966.4 Cr a year ago and 6.3% from Rs 2,229.40 Cr in the previous quarter, as the Jubilant Pharmova Q2 Results FY27 filing records.
- Net profit of Rs 31 Cr: PAT fell 74.15% from Rs 119.9 Cr, the widest YoY decline among the headline lines.
- Operating Profit of Rs 240.5 Cr: this line fell 29.55% from Rs 341.4 Cr, moving against the 20.52% rise in revenue.
- Net profit margin of 1.3%: the margin narrowed from 6.1% in the comparison quarter on the reported figures.
- Next step: the performance analysis below sets out how revenue, Operating Profit and net profit moved apart.
Jubilant Pharmova Q2 Results FY27: Performance Analysis
Jubilant Pharmova reported consolidated revenue of Rs 2,370 Cr in Q2 FY27, up 20.52% YoY, while net profit fell 74.15% to Rs 31 Cr. Operating Profit declined to Rs 240.5 Cr, so the quarterly results show revenue growth that did not carry through to profit.
In Jubilant Pharmova Q2 Results FY27, revenue gained Rs 403.6 Cr over the Rs 1,966.4 Cr base, while net profit fell Rs 88.9 Cr from the Rs 119.9 Cr base. Operating Profit fell Rs 100.9 Cr from Rs 341.4 Cr, which this results analysis treats as the main point of contrast.
Investors following Jubilant Pharmova Q2 Results FY27 will want to see whether the 20.52% YoY growth in revenue starts to reach net profit in later disclosures, because the Jubilant Pharmova Q2 Results figures on the Consolidated basis form the base for that comparison. That question is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Year-on-year revenue growth – The results analysis points to revenue growth of 20.5% YoY to Rs 2,370.00 Cr as the first factor behind the quarterly results, well above the Rs 1,966.4 Cr recorded a year earlier.
Sequential revenue growth – Revenue was up 6.3% quarter on quarter from Rs 2,229.40 Cr, and Jubilant Pharmova Q2 Results FY27 show that the Consolidated top line has risen over the previous quarter as well as over the year.
Profit lines against revenue – Operating Profit of Rs 240.5 Cr and net profit of Rs 31 Cr both fell YoY while revenue rose, a pattern that frames the FY27 outlook that follows.
FY27 Outlook After Jubilant Pharmova Q2 Results
The FY27 outlook after Jubilant Pharmova Q2 Results FY27 rests on what the coming quarters add to the Rs 31 Cr net profit recorded here. Full-year FY27 results will depend on subsequent quarterly disclosures, and this results analysis rests only on the reported figures rather than on management guidance.
Investors can watch whether revenue holds near the Rs 2,370 Cr level and whether Operating Profit, at Rs 240.5 Cr, moves closer to the Rs 341.4 Cr of a year ago. The risks that could shape those readings are set out next.
Key Risks to Watch After Jubilant Pharmova Q2 Results FY27
Lower Net Profit
Net profit fell 74.1% YoY to Rs 31.00 Cr, a decline that Jubilant Pharmova Q2 Results FY27 place against the 20.52% YoY growth in revenue, so the step from revenue to profit is the first item investors will track.
Narrower Net Profit Margin
Net profit margin narrowed to 1.3% from 6.1% in the comparison quarter, a gap of 4.8 percentage points that sits beside the 29.55% fall in Operating Profit.
Low Returns on Equity and Capital
Return on equity was low at 5.97% in FY26, and return on capital employed was modest at 8.69%, two full-year readings that investors consider beside the Rs 31 Cr net profit for Q2 FY27.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Jubilant Pharmova Q2 Results FY27 show revenue up 20.52% to Rs 2,370 Cr and net profit down 74.15% to Rs 31 Cr, while Operating Profit fell 29.55%. The Consolidated filing therefore shows revenue and profit moving in different directions. These quarterly results, filed as consolidated results, give a base for tracking Jubilant Pharmova Q2 Results against later periods, and investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Jubilant Pharmova Q2 Results FY27
What are Jubilant Pharmova Q2 Results FY27?
Ans. Jubilant Pharmova Q2 Results FY27 cover the July to September 2026 quarter on a Consolidated basis, with revenue of Rs 2,370 Cr and net profit of Rs 31 Cr, as the Financial Highlights section shows.
What is the results date for Jubilant Pharmova Q2 Results FY27?
Ans. Jubilant Pharmova declared its Q2 FY27 results on 13 November 2026. The results date also marks the filing from which every revenue and net profit figure here is taken, as the introduction explains.
What revenue was reported in Jubilant Pharmova Q2 Results FY27?
Ans. Jubilant Pharmova reported consolidated revenue of Rs 2,370 Cr in Q2 FY27, compared with Rs 1,966.4 Cr a year earlier, which means revenue rose Rs 403.6 Cr, as the Performance Analysis section shows.
What net profit was reported in Jubilant Pharmova Q2 Results FY27?
Ans. Jubilant Pharmova reported net profit of Rs 31 Cr for Q2 FY27 against Rs 119.9 Cr in the same quarter last year, so net profit fell Rs 88.9 Cr, as the Key Takeaways section notes.
How much YoY growth did revenue show in Jubilant Pharmova Q2 Results FY27?
Ans. Jubilant Pharmova Q2 Results FY27 show revenue YoY growth of 20.52%, from Rs 1,966.4 Cr to Rs 2,370 Cr, while net profit fell 74.15%, which the Performance Analysis section covers in more detail.
Did net profit rise or fall in Jubilant Pharmova Q2 Results?
Ans. Jubilant Pharmova Q2 Results show net profit fell 74.15% YoY to Rs 31 Cr from Rs 119.9 Cr, while the net profit margin narrowed to 1.3% from 6.1%, as the Key Risks section explains.
What was the Operating Profit in Jubilant Pharmova Q2 Results FY27?
Ans. Operating Profit in Jubilant Pharmova Q2 Results FY27 was Rs 240.5 Cr against Rs 341.4 Cr a year earlier, a 29.55% decline, which contrasts with the revenue growth in the Performance Analysis section.
Are Jubilant Pharmova Q2 Results consolidated results or standalone results?
Ans. The Jubilant Pharmova Q2 Results are consolidated results, so the revenue of Rs 2,370 Cr and net profit of Rs 31 Cr cover the group, as the opening paragraphs of this article state.
What business factors shaped Jubilant Pharmova Q2 Results FY27?
Ans. Revenue growth of 20.5% YoY and a 6.3% quarter on quarter rise from Rs 2,229.40 Cr shaped Jubilant Pharmova Q2 Results FY27, as the Key Business Factors section details.
What are the key risks after Jubilant Pharmova Q2 Results FY27?
Ans. A 74.1% fall in net profit, a margin of 1.3% against 6.1% and return on equity of 5.97% in FY26 are the key risks after Jubilant Pharmova Q2 FY27, as the Key Risks section lists.
What is the outlook after Jubilant Pharmova Q2 Results?
Ans. Full-year FY27 results will depend on the quarters that follow the Rs 31 Cr net profit reported here, so the Outlook section rests on reported figures rather than on management guidance.
Where can I find the complete Jubilant Pharmova Q2 Results FY27 data?
Ans. The Financial Highlights table above lists every headline figure from the 13 November 2026 filing, while the Univest Screener and the Univest app offer more on Jubilant Pharmova beyond this article.
